Metabolic and Prolonged Satiety Effects of a Breakfast Kit

Universidade do Porto

Status

Unknown

Conditions

Diet Habit

Treatments

Other: MobFood breakfast kit

Other: Control isocaloric breakfast

Study type

Interventional

Funder types

Other

Identifiers

NCT04417504

MobFood

Details and patient eligibility

About

The mobilizing programme MobFood - mobilizing scientific knoweledge and technology to answer the current nutrition market challenges - is formed by a consortium of 47 collaborative entities, between the industry and ENESIIs (Entidades Não Empresariais do Sistema de Investigação e Inovação) and is financed by Structural European Funds of Investment.

The project is currently investigating and undertaking collaborative scientific and technological strategies based on R&D and innovation, in order to boost and promote a more competitive national food industry, capable of overcoming the current challenges, including those of the Millennial Generation. This group is particularly conscious of the impact of food behaviour and food choices on health but extremely vulnerable to dietary imbalance. Strategies to improve Millenials' nutrition while providing conscious food products are needed.

This study is a randomised, cross-over controlled trial designed to test the metabolic effect, particularly in terms of appetite control and glycaemic response of a breakfast kit (nutritionally balanced and innovative), recently developed as part of the collaborative project MobFood_PPS4.

Enrollment

15 estimated patients

Sex

All

Ages

23 to 38 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female;
Born between 1981 and 1996;
Body mass index (BMI) between 18.5 kg/m2 and 24.9 kg/m2;
Normoglycemic according to American Diabetes Association criteria [Fasting Plasma Glucose < 100 mg/dl, 2-h plasma glucose value during a 75 g oral glucose tolerance test (OGTT) < 140 mg/dl)];
Healthy.

Exclusion criteria

Overweight or obese (BMI ≥ 25,0 kg/m2);
Recent body weight loss/gain >10%, within previous 3 months;
Being on a weight loss/other special diet (e.g. Paleo diet, Atkins diet, flexitarian diet or ketogenic diet), within previous 3 months;
Clinically significant illness, including:

type 1 or type 2 diabetes; liver disease e.g. cirrhosis; malignancy; pancreatitis or other malabsorption; gastrointestinal disorders e. g. intestinal bowel disorder, celiac disease; previous weight loss surgery e.g. bariatric surgery; chronic respiratory, neurological, psychiatric, musculoskeletal diseases/conditions; diagnosed eating disorders.

Individuals who don't regularly consume breakfast;
Having taken antibiotics within the 12 weeks prior to beginning the study;
Taking other medication that could potentially affect body weight, glucose metabolism and/or appetite (e.g. GLP-1 analogues);
Being engaged in competitive sports;
Having >14 or >8 (males and females, respectively) alcoholic units/week; misuse of drugs;
Having donated blood within one month prior to the beginning of the study;
Nut or milk allergy, or other food allergy or intolerance that would compromise compliance with the study protocol;
Pregnant or breastfeeding.